Amicus Therapeutics, Inc. (NASDAQ:FOLD) Expected to Post Earnings of -$0.28 Per Share

Brokerages expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings per share (EPS) of ($0.28) for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Amicus Therapeutics’ earnings. The lowest EPS estimate is ($0.37) and the highest is ($0.21). Amicus Therapeutics reported earnings per share of ($0.41) in the same quarter last year, which indicates a positive year-over-year growth rate of 31.7%. The business is scheduled to report its next quarterly earnings results on Thursday, February 27th.

On average, analysts expect that Amicus Therapeutics will report full-year earnings of ($1.41) per share for the current financial year, with EPS estimates ranging from ($1.50) to ($1.33). For the next fiscal year, analysts expect that the company will report earnings of ($0.87) per share, with EPS estimates ranging from ($1.11) to ($0.70). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Amicus Therapeutics.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.08. Amicus Therapeutics had a negative net margin of 216.02% and a negative return on equity of 62.61%. The business had revenue of $48.80 million for the quarter, compared to the consensus estimate of $48.05 million. During the same period last year, the firm posted ($0.84) earnings per share. Amicus Therapeutics’s quarterly revenue was up 136.9% on a year-over-year basis.

Several equities research analysts have issued reports on FOLD shares. ValuEngine lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 4th. BidaskClub raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 21st. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Amicus Therapeutics in a research note on Thursday, November 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Amicus Therapeutics in a report on Thursday, October 17th. Finally, Cowen set a $31.00 target price on shares of Amicus Therapeutics and gave the stock a “buy” rating in a research report on Thursday, October 10th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Amicus Therapeutics currently has an average rating of “Buy” and an average price target of $17.97.

In other news, CEO John F. Crowley sold 40,000 shares of Amicus Therapeutics stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $10.01, for a total transaction of $400,400.00. Following the sale, the chief executive officer now owns 775,694 shares of the company’s stock, valued at approximately $7,764,696.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John F. Crowley sold 20,000 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.38, for a total value of $207,600.00. Following the sale, the chief executive officer now directly owns 755,694 shares in the company, valued at $7,844,103.72. The disclosure for this sale can be found here. Insiders sold 134,500 shares of company stock worth $1,295,945 over the last three months. 2.50% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in FOLD. Jane Street Group LLC grew its holdings in Amicus Therapeutics by 15.6% in the second quarter. Jane Street Group LLC now owns 43,078 shares of the biopharmaceutical company’s stock worth $538,000 after purchasing an additional 5,812 shares during the period. Meeder Asset Management Inc. bought a new position in Amicus Therapeutics during the 2nd quarter valued at approximately $73,000. Marshall Wace LLP increased its position in Amicus Therapeutics by 339.2% during the 2nd quarter. Marshall Wace LLP now owns 742,236 shares of the biopharmaceutical company’s stock valued at $9,263,000 after buying an additional 573,235 shares in the last quarter. UBS Asset Management Americas Inc. raised its stake in Amicus Therapeutics by 31.8% during the second quarter. UBS Asset Management Americas Inc. now owns 207,986 shares of the biopharmaceutical company’s stock valued at $2,596,000 after buying an additional 50,218 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Amicus Therapeutics during the third quarter valued at $1,479,000.

Shares of NASDAQ:FOLD opened at $10.11 on Friday. The firm has a market capitalization of $2.58 billion, a PE ratio of -7.60 and a beta of 1.57. The company has a debt-to-equity ratio of 0.36, a quick ratio of 6.10 and a current ratio of 6.20. Amicus Therapeutics has a 52-week low of $7.11 and a 52-week high of $14.61. The firm has a fifty day moving average of $9.28 and a 200 day moving average of $10.44.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

See Also: What are economic reports?

Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.